NCT03319732View on ClinicalTrials.gov

A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS

PHASE3CompletedINTERVENTIONAL
Enrollment

323

Participants

Timeline

Start Date

April 3, 2018

Primary Completion Date

January 27, 2020

Study Completion Date

June 11, 2020

Conditions
Multiple SclerosisSpasticity, Muscle
Interventions
DRUG

Arbaclofen

Arbaclofen is the active R enantiomer of baclofen.

Trial Locations (1)

93710

Neuro Pain Medical Center, Fresno

Sponsors
All Listed Sponsors
collaborator

Osmotica Pharmaceutical US LLC

INDUSTRY

lead

RVL Pharmaceuticals, Inc.

INDUSTRY